RNA- Based Drug Delivery, Current Advances, Pharmaceutical Applications, and Future Perspectives

Year : 2026 | Volume : 13 | 02 | Page :
    By

    Aayush K. Ramraje,

  • Bhupendra M. Mahale,

  • Akshata M. Girase,

  • Ghanshyam M. Chavan,

  1. Research Scholar, Dr. Babasaheb Ambedkar Technological University Lonere, Raigad, Maharashtra, SVS’s Dadasaheb Rawal Pharmacy College Dondaicha -425408, Maharashtra, India
  2. Assistant Professor, Department of Pharmaceutics, P.S.G.V.P. Mandal’s College of Pharmacy, Shahada, Dist. Nandurbar Affiliated with KBCNMU Jalgaon, Maharashtra, India
  3. Assistant Professor, Pharmaceutical Quality Assurance, Babasaheb Ambedkar Technological University, Lonere, Raigad, Maharashtra, India
  4. Principal, SVS’s Dadasaheb Rawal Pharmacy College Mandal – Dondaicha, 425408, Maharashtra, India

Abstract

RNA-based therapeutics have emerged as a transformative approach in modern medicine due to their ability to regulate gene expression with high specificity and precision. Advances in molecular biology, RNA chemistry, and nanotechnology have accelerated the development of diverse RNA modalities, including messenger RNA (mRNA), small interfering RNA (siRNA), microRNA (miRNA), antisense oligonucleotides (ASOs), and RNA aptamers. These therapeutics offer promising strategies for the treatment of cancer, genetic disorders, infectious diseases, neurological conditions, and cardiovascular diseases. However, the clinical translation of RNA therapies is challenged by issues such as poor stability, rapid degradation by nucleases, limited cellular uptake, immunogenicity, and off-target effects. Recent innovations in delivery technologies, particularly lipid nanoparticles, viral vectors, extracellular vesicles, polymeric carriers, and other nanomaterial-based systems, have significantly improved the safety and efficacy of RNA delivery. The successful application of mRNA vaccines during the COVID-19 pandemic has further highlighted the therapeutic potential of RNA platforms. This review summarizes the different classes of RNA therapeutics, their mechanisms of action, pharmaceutical applications, and the latest advances in delivery systems. Additionally, current challenges and future perspectives in the field are discussed, emphasizing the need for targeted, tissue-specific, and personalized RNA-based treatment strategies. Continued progress in RNA engineering and delivery technologies is expected to expand the clinical utility of RNA therapeutics and establish them as a cornerstone of precision medicine.

Keywords: RNA therapeutics, RNA-based drug delivery, mRNA, siRNA, antisense oligonucleotides, lipid nanoparticles, nanocarriers, gene therapy, precision medicine, pharmaceutical applications.

How to cite this article:
Aayush K. Ramraje, Bhupendra M. Mahale, Akshata M. Girase, Ghanshyam M. Chavan. RNA- Based Drug Delivery, Current Advances, Pharmaceutical Applications, and Future Perspectives. Research & Reviews: A Journal of Drug Design & Discovery. 2026; 13(02):-.
How to cite this URL:
Aayush K. Ramraje, Bhupendra M. Mahale, Akshata M. Girase, Ghanshyam M. Chavan. RNA- Based Drug Delivery, Current Advances, Pharmaceutical Applications, and Future Perspectives. Research & Reviews: A Journal of Drug Design & Discovery. 2026; 13(02):-. Available from: https://journals.stmjournals.com/rrjoddd/article=2026/view=248978


References

1. De Mey W, Esprit A, Thielemans K, Breckpot K, Franceschini L. Rna in cancer immunotherapy: unlocking the potential of the immune system. Clin Cancer Res. 2022;28(18):3929–39. https://doi.org/10.1158/1078-0432.CCR-21-3304.
2. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA. 1978; 75:280–4.
3. WangWang F, Zuroske T, Watts JK. RNA therapeutics on the rise. Nat Rev Drug Discov. 2020; 19:441–2.
4. Guerrier-Takada C, Gardiner K, Marsh T, Pace N, Altman S. The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme. Cell. 1983; 35:849–857. [PubMed: 6197186].
5. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998; 391:806–811. [PubMed: 9486653].
6. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA. 1978;75:280–4.
7. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494–8.
8. Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA targeted therapeutics. Cell Metab. 2018; 27:714–39.
9. Falese J, Donlic A, Hargrove A. Targeting RNA with small molecules: from fundamental principles towards the clinic. Chem Soc Rev. 2021; 50:2224–43.
10. Wolff, J.A.; Malone, R.W.; Williams, P.; Chong, W.; Acsadi, G.; Jani, A.; Felgner, P.L. Direct gene transfer into mouse muscle in vivo. Science 1990, 247 Pt 1, 1465–1468. [CrossRef] [PubMed].
11. Hu, B.; Zhong, L.; Weng, Y.; Peng, L.; Huang, Y.; Zhao, Y.; Liang, X.J. Therapeutic siRNA: State of the art. Signal Transduct. Target. Ther. 2020, 5, 101. [CrossRef] [PubMed].
12. Vienberg, S.; Geiger, J.; Madsen, S.; Dalgaard, L.T. MicroRNAs in metabolism. Acta Physiol. 2017, 219, 346–361. [CrossRef].
13. Melnikova I. RNA-based therapies. Nature Reviews Drug Discovery. 2007; 6:863–864.
14. Wang F, Zuroske T, Watts JK. RNA therapeutics on the rise. Nat Rev Drug Discov. 2020;19:441–2.
15. Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA-targeted therapeutics. Cell Metab. 2018;27:714–39.
16. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21 nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001; 411:494–8.
17. U, Karikó K, Türeci Ö. mRNA based therapeutics – developing a new class of drugs. Nat Rev Drug Discov. 2014; 13:759–80.
18. Adachi T, Nakamura Y. Aptamers: a review of their chemical properties and modifications for therapeutic application. Molecules. 2019; 24:4229.
19. Peer D, Lieberman J. Special delivery: targeted therapy with small RNAs. Gene Ther. 2011.
20. Shukla S, Sumaria CS, Pradeepkumar PI. Exploring chemical modifications for siRNA therapeutics: a structural and functional outlook. ChemMedChem. 2010; 5:328–349. [PubMed: 20043313].
21. WangWang F, Zuroske T, Watts JK. RNA therapeutics on the rise. Nat Rev Drug Discov. 2020; 19:441–2.
22. Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA targeted therapeutics. Cell Metab. 2018; 27:714–39.
23. Molecular Cancer. Advances in RNA based cancer therapeutics: pre clinical and clinical implications [Open access review]. Molecular Cancer. 2025; 24:251.
24. Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA targeted therapeutics. Cell Metab. 2018; 27:714–39.
25. Falese J, Donlic A, Hargrove A. Targeting RNA with small molecules: from fundamental principles towards the clinic. Chem Soc Rev. 2021; 50:2224–43.
26. Liang XH, Sun H, Nichols JG, Crooke ST. RNase H1 dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus. Mol Ther. 2017; 25:2075–92.
27. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21 nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001; 411:494–8.
28. Liang XH, Sun H, Nichols JG, Crooke ST. RNase H1 dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus. Mol Ther. 2017; 25:2075–92.
29. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21 nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001; 411:494–8.
30. Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA targeted therapeutics. Cell Metab. 2018; 27:714–39.
31. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA. 1978; 75:280–4.
32. Liang XH, Sun H, Nichols JG, Crooke ST. RNase H1 dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus. Mol Ther. 2017; 25:2075–92.
33. U, Karikó K, Türeci Ö. mRNA based therapeutics – developing a new class of drugs. Nat Rev Drug Discov. 2014; 13:759–80.
34. WangWang F, Zuroske T, Watts JK. RNA therapeutics on the rise. Nat Rev Drug Discov. 2020; 19:441–2.
35. Falese J, Donlic A, Hargrove A. Targeting RNA with small molecules: from fundamental principles towards the clinic. Chem Soc Rev. 2021; 50:2224–43.
36. Adachi T, Nakamura Y. Aptamers: a review of their chemical properties and modifications for therapeutic application. Molecules. 2019; 24:4229.
37. Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA targeted therapeutics. Cell Metab. 2018; 27:714–39.
38. Liang XH, Sun H, Nichols JG, Crooke ST. RNase H1 dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus. Mol Ther. 2017; 25:2075–92.
39. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21 nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001; 411:494–8.
40. U, Karikó K, Türeci Ö. mRNA based therapeutics – developing a new class of drugs. Nat Rev Drug Discov. 2014; 13:759–80.
41. Liang XH, Sun H, Nichols JG, Crooke ST. RNase H1 dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus. Mol Ther. 2017; 25:2075–92.
42. Wang F, Wang L, Zou X, et al. Advances in CRISPR Cas systems for RNA targeting, tracking and editing. Biotechnol Adv. 2019; 37:708–29.
43. Wang Y, Miao L, Satterlee A, Huang L. Delivery of oligonucleotides with lipid nanoparticles. Adv Drug Deliv Rev. 2015;87:68–80.
44. Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein G. Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev. 2015;87:108–19.
45. Cheng X, Lee RJ. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Adv Drug Deliv Rev. 2016;99:129–37.
46. Harvie P, Wong FM, Bally MB. Use of poly(ethylene glycol)-lipid conjugates to regulate the surface attributes and transfection activity of lipid-DNA particles. J Pharm Sci. 2000;89:652–63.
47. Witzigmann D, Kulkarni JA, Leung J, Chen S, Cullis PR, van der Meel R. Lipid nanoparticle technology for therapeutic gene regulation in the liver. Adv Drug Deliv Rev. 2020;159:344–63.
48. Gilleron J, Querbes W, Zeigerer A, Borodovsky A, Marsico G, Schubert U, et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol. 2013;31:638–46.
49. Yin Y, Li X, Ma H, Zhang J, Yu D, Zhao R, et al. In situ transforming RNA nanovaccines from polyethylenimine functionalized graphene oxide hydrogel for durable cancer immunotherapy. Nano Lett. 2021;21:2224–31.
50. Höbel S, Appeldoorn CC, Gaillard PJ, Aigner A. Targeted CRM197-PEG-PEI/ siRNA Complexes for Therapeutic RNAi in Glioblastoma. Pharmaceuticals. 2011;4:1591–606.
51. Pandey AP, Sawant KK. Polyethylenimine: a versatile, multifunctional nonviral vector for nucleic acid delivery. Mater Sci Eng C Mater Biol Appl. 2016;68:904–18.
52. Mao S, Sun W, Kissel T. Chitosan-based formulations for delivery of DNA and siRNA. Adv Drug Deliv Rev. 2010;62:12–27.
53. Pandey AP, Sawant KK. Polyethylenimine: a versatile, multifunctional nonviral vector for nucleic acid delivery. Mater Sci Eng C Mater Biol Appl. 2016;68:904–18.
54. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010;464:1067–70.
55. Davis ME. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm. 2009;6:659–68.
56. WangWang F, Zuroske T, Watts JK. RNA therapeutics on the rise. Nat Rev Drug Discov. 2020; 19:441–2.
57. Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA targeted therapeutics. Cell Metab. 2018; 27:714–39.
58. Molecular Cancer. Advances in RNA based cancer therapeutics: pre clinical and clinical implications [Open access review]. Molecular Cancer. 2025; 24:251.
59. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA. 1978; 75:280–4.
60. Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA targeted therapeutics. Cell Metab. 2018; 27:714–39.
61. Molecular Cancer. Advances in RNA based cancer therapeutics: pre clinical and clinical implications [Open access review]. Molecular Cancer. 2025; 24:251.
62. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA. 1978; 75:280–4.
63. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21 nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001; 411:494–8.
64. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21 nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001; 411:494–8.
65. Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA targeted therapeutics. Cell Metab. 2018; 27:714–39.
66. Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA targeted therapeutics. Cell Metab. 2018; 27:714–39.
67. WangWang F, Zuroske T, Watts JK. RNA therapeutics on the rise. Nat Rev Drug Discov. 2020; 19:441–2.
68. Dowdy SF. Overcoming cellular barriers for RNA therapeutics. Nat Biotechnol. 2017;35:222–9.
69. Khvorova A, Watts JK. The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol. 2017;35:238–48.
70. Bramsen JB, Kjems J. Development of therapeutic-grade small interfering RNAs by chemical engineering. Front Genet. 2012;3:154.
71. Chen X, Mangala LS, Rodriguez-Aguayo C, Kong X, Lopez-Berestein G, Sood AK. RNA interference-based therapy and its delivery systems. Cancer Metastasis Rev. 2018;37:107–24.
72. Ho W, Zhang XQ, Xu X. Biomaterials in siRNA delivery: a comprehensive review. Adv Health Mater. 2016;5:2715–31.
73. Finer, M.; Glorioso, J. A brief account of viral vectors and their promise for gene therapy. Gene Ther. 2017, 24, 1–2. [CrossRef].
74. Wang, D.; Tai, P.W.L.; Gao, G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat. Rev. Drug Discov. 2019, 18, 358–378. [CrossRef].
75. Thomas, C.E.; Ehrhardt, A.; Kay, M.A. Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 2003, 4, 346–358. [CrossRef].
76. Lundstrom, K. Viral Vectors in Gene Therapy: Where Do We Stand in 2023? Viruses 2023, 15, 698. [CrossRef].
77. Zhao, Z.; Anselmo, A.C.; Mitragotri, S. Viral vector-based gene therapies in the clinic. Bioeng. Transl. Med. 2022, 7, e10258. [CrossRef] [PubMed].
78. Zhao, Z.; Anselmo, A.C.; Mitragotri, S. Viral vector-based gene therapies in the clinic. Bioeng. Transl. Med. 2022, 7, e10258. [CrossRef] [PubMed].
79. Lewin, A.S.; Hauswirth, W.W. Ribozyme gene therapy: Applications for molecular medicine. Trends Mol. Med. 2001, 7, 221–228. [CrossRef].
80. Garbo, S.; Maione, R.; Tripodi, M.; Battistelli, C. Next RNA Therapeutics: The Mine of Non-Coding. Int. J. Mol. Sci. 2022, 23, 7471. [CrossRef].
81. Chung, Y.H.; Cai, H.; Steinmetz, N.F. Viral nanoparticles for drug delivery, imaging, immunotherapy, and theranostic applications. Adv. Drug Deliv. Rev. 2020, 156, 214–235. [CrossRef].
82. Lyu, P.; Wang, L.; Lu, B. Virus-Like Particle Mediated CRISPR/Cas9 Delivery for Efficient and Safe Genome Editing. Life 2020, 10, 366. [CrossRef].
83. Lyu, P.; Lu, B. New Advances in Using Virus-like Particles and Related Technologies for Eukaryotic Genome Editing Delivery. Int. J. Mol. Sci. 2022, 23, 8750. [CrossRef].
84. Segel, M.; Lash, B.; Song, J.; Ladha, A.; Liu, C.C.; Jin, X.; Mekhedov, S.L.; Macrae, R.K.; Koonin, E.V.; Zhang, F. Mammalian retrovirus-like protein PEG10 packages its own mRNA and can be pseudotyped for mRNA delivery. Science 2021, 373, 882–889. [CrossRef] [PubMed].
85. Allen, T.M.; Cullis, P.R. Liposomal drug delivery systems: From concept to clinical applications. Adv. Drug Deliv. Rev. 2013, 65, 36–48. [CrossRef].
86. Filipczak, N.; Pan, J.; Yalamarty, S.S.K.; Torchilin, V.P. Recent advancements in liposome technology. Adv. Drug Deliv. Rev. 2020, 156, 4–22. [CrossRef].
87. Cullis, P.R.; Hope, M.J. Lipid Nanoparticle Systems for Enabling Gene Therapies. Mol. Ther. 2017, 25, 1467–1475. [CrossRef].
88. Thi, T.T.H.; Suys, E.J.A.; Lee, J.S.; Nguyen, D.H.; Park, K.D.; Truong, N.P. Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines. Vaccines 2021, 9, 359. [CrossRef].
89. Thery, C.; Witwer, K.W.; Aikawa, E.; Alcaraz, M.J.; Anderson, J.D.; Andriantsitohaina, R.; Antoniou, A.; Arab, T.; Archer, F.; Atkin-Smith, G.K.; et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J. Extracell. Vesicles 2018, 7, 1535750. [CrossRef] [PubMed].
90. Barile, L.; Vassalli, G. Exosomes: Therapy delivery tools and biomarkers of diseases. Pharmacol. Ther. 2017, 174, 63–78. [CrossRef].
91. Wedge, M.-E.; Jennings, V.A.; Crupi, M.J.F.; Poutou, J.; Jamieson, T.; Pelin, A.; Pugliese, G.; de Souza, C.T.; Petryk, J.; Laight, B.J.; et al. Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy. Nat. Commun. 2022, 13, 1898. [CrossRef] [PubMed].
92. Gu, W.; Luozhong, S.; Cai, S.; Londhe, K.; Elkasri, N.; Hawkins, R.; Yuan, Z.; Su-Greene, K.; Yin, Y.; Cruz, M.; et al. Extracellular vesicles incorporating retrovirus-like capsids for the enhanced packaging and systemic delivery of mRNA into neurons. Nat. Biomed. Eng. 2024, 8, 415–426. [CrossRef].
93. Dong, S.; Liu, X.; Bi, Y.; Wang, Y.; Antony, A.; Lee, D.; Huntoon, K.; Jeong, S.; Ma, Y.; Li, X.; et al. Adaptive design of mRNA-loaded extracellular vesicles for targeted immunotherapy of cancer. Nat. Commun. 2023, 14, 6610. [CrossRef].
94. Hou, X.; Zaks, T.; Langer, R.; Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 2021, 6, 1078–1094. [CrossRef].
95. Tenchov, R.; Bird, R.; Curtze, A.E.; Zhou, Q. Lipid Nanoparticles—From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement. ACS Nano 2021, 15, 16982–17015. [CrossRef].
96. Xue, H.Y.; Liu, S.; Wong, H.L. Nanotoxicity: A key obstacle to clinical translation of siRNA-based nanomedicine. Nanomedicine 2014, 9, 295–312. [CrossRef].
97. Ho, W.; Gao, M.; Li, F.; Li, Z.; Zhang, X.Q.; Xu, X. Next-Generation Vaccines: Nanoparticle-Mediated DNA and mRNA Delivery. Adv. Healthc. Mater. 2021, 10, e2001812. [CrossRef].
98. Xue, H.Y.; Liu, S.; Wong, H.L. Nanotoxicity: A key obstacle to clinical translation of siRNA-based nanomedicine. Nanomedicine 2014, 9, 295–312. [CrossRef].
99. Ho, W.; Gao, M.; Li, F.; Li, Z.; Zhang, X.Q.; Xu, X. Next-Generation Vaccines: Nanoparticle-Mediated DNA and mRNA Delivery. Adv. Healthc. Mater. 2021, 10, e2001812. [CrossRef].
100. Smith, S.A.; Selby, L.I.; Johnston, A.P.R.; Such, G.K. The Endosomal Escape of Nanoparticles: Toward More Efficient Cellular Delivery. Bioconjug Chem. 2019, 30, 263–272. [CrossRef].
101. Cao, Y.; Tan, Y.F.; Wong, Y.S.; Liew, M.W.J.; Venkatraman, S. Recent Advances in Chitosan-Based Carriers for Gene Delivery. Mar. Drugs 2019, 17, 381. [CrossRef] [PubMed].
102. Soliman, O.Y.; Alameh, M.G.; De Cresenzo, G.; Buschmann, M.D.; Lavertu, M. Efficiency of Chitosan/Hyaluronan-Based mRNA Delivery Systems In Vitro: Influence of Composition and Structure. J. Pharm. Sci. 2020, 109, 1581–1593. [CrossRef].
103. Lee, W.-J.; Kim, K.-J.; Hossain, M.K.; Cho, H.-Y.; Choi, J.-W. DNA–Gold Nanoparticle Conjugates for Intracellular miRNA Detection Using Surface-Enhanced Raman Spectroscopy. BioChip J. 2022, 16, 33–40. [CrossRef].
104. guyen, M.A.; Wyatt, H.; Susser, L.; Geoffrion, M.; Rasheed, A.; Duchez, A.C.; Cottee, M.L.; Afolayan, E.; Farah, E.; Kahiel, Z.; et al. Delivery of MicroRNAs by Chitosan Nanoparticles to Functionally Alter Macrophage Cholesterol Efflux in Vitro and in Vivo. ACS Nano 2019, 13, 6491–6505. [CrossRef].
105. Pilipenko, I.; Korzhikov-Vlakh, V.; Sharoyko, V.; Zhang, N.; Schäfer-Korting, M.; Rühl, E.; Zoschke, C.; Tennikova, T. pH-Sensitive Chitosan-Heparin Nanoparticles for Effective Delivery of Genetic Drugs into Epithelial Cells. Pharmaceutics 2019, 11, 317. [CrossRef].
106. Shtykalova, S.; Deviatkin, D.; Freund, S.; Egorova, A.; Kiselev, A. Non-Viral Carriers for Nucleic Acids Delivery: Fundamentals and Current Applications. Life 2023, 13, 903. [CrossRef].
107. Jones, S.W.; Christison, R.; Bundell, K.; Voyce, C.J.; Brockbank, S.M.; Newham, P.; Lindsay, M.A. Characterisation of cellpenetrating peptide-mediated peptide delivery. Br. J. Pharmacol. 2005, 145, 1093–1102. [CrossRef].
108. Shoari, A.; Tooyserkani, R.; Tahmasebi, M.; Löwik, D. Delivery of Various Cargos into Cancer Cells and Tissues via Cell-Penetrating Peptides: A Review of the Last Decade. Pharmaceutics 2021, 13, 1391. [CrossRef].
109. Krhaˇc Levaˇci´c, A.; Berger, S.; Müller, J.; Wegner, A.; Lächelt, U.; Dohmen, C.; Rudolph, C.; Wagner, E. Dynamic mRNA polyplexes benefit from bioreducible cleavage sites for in vitro and in vivo transfer. J. Control. Release 2021, 339, 27–40. [CrossRef] [PubMed].
110. Jensen, S.A.; Day, E.S.; Ko, C.H.; Hurley, L.A.; Luciano, J.P.; Kouri, F.M.; Merkel, T.J.; Luthi, A.J.; Patel, P.C.; Cutler, J.I.; et al. Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci. Transl. Med. 2013, 5, 209ra152. [CrossRef] [PubMed].
111. Li, J.; Chen, Y.-C.; Tseng, Y.-C.; Mozumdar, S.; Huang, L. Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J. Control. Release 2010, 142, 416–421. [CrossRef].
112. Li, Y.; Wang, X.; Zhang, Y.; Nie, G. Recent Advances in Nanomaterials with Inherent Optical and Magnetic Properties for Bioimaging and Imaging-Guided Nucleic Acid Therapy. Bioconjugate Chem. 2020, 31, 1234–1246. [CrossRef] [PubMed].
113. Han, X.; Mitchell, M.J.; Nie, G. Nanomaterials for Therapeutic RNA Delivery. Matter 2020, 3, 1948–1975. [CrossRef].
114. Lu, Q.; Wright, A.; Pan, Z.-H. AAV dose-dependent transduction efficiency in retinal ganglion cells and functional efficacy of optogenetic vision restoration. Gene Ther. 2024, 31, 572–579. [CrossRef] [PubMed].
115. Costa Verdera, H.; Kuranda, K.; Mingozzi, F. AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer. Mol. Ther. 2020, 28, 723–746. [CrossRef].
116. Kamola PJ, Nakano Y, Takahashi T, Wilson PA, Ui-Tei K. The siRNA non-seed region and its target sequences are auxiliary determinants of off-target effects. PLoS Comput Biol. 2015;11:e1004656.
117. WangWang F, Zuroske T, Watts JK. RNA therapeutics on the rise. Nat Rev Drug Discov. 2020; 19:441–2.
118. Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA targeted therapeutics. Cell Metab. 2018; 27:714–39.
119. U, Karikó K, Türeci Ö. mRNA based therapeutics – developing a new class of drugs. Nat Rev Drug Discov. 2014; 13:759–80.
120. Molecular Cancer. Advances in RNA based cancer therapeutics: pre clinical and clinical implications [Open access review]. Molecular Cancer. 2025; 24:251.
121. Zakas, P.M.; Cunningham, S.C.; Doherty, A.; van Dijk, E.B.; Ibraheim, R.; Yu, S.; Mekonnen, B.D.; Lang, B.; English, E.J.; Sun, G.; et al. Sleeping Beauty mRNA-LNP enables stable rAAV transgene expression in mouse and NHP hepatocytes and improves vector potency. Mol. Ther. 2024, 32, 3356–3371. [CrossRef].
122. Chen QX, Wang WP, Zeng S, Urayama S, Yu AM. A general approach to highyield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications. Nucleic Acids Res. 2015;43:3857–69.
123. Patel S, Kim J, Herrera M, Mukherjee A, Kabanov AV, Sahay G. Brief update on endocytosis of nanomedicines. Adv Drug Deliv Rev. 2019;144:90–111.
124. Paunovska K, Loughrey D, Sago CD, Langer R, Dahlman JE. Using large datasets to understand nanotechnology. Adv Mater. 2019;31:e1902798.
125. Zhang, R.; Wu, M.; Xiang, D.; Zhu, J.; Zhang, Q.; Zhong, H.; Peng, Y.; Wang, Z.; Ma, G.; Li, G.; et al. A primate-specific endogenous retroviral envelope protein sequesters SFRP2 to regulate human cardiomyocyte development. Cell Stem Cell 2024, 31, 1298–1314.e8. [CrossRef].

Ahead of Print Subscription Review Article
Volume 13
02
Received 07/06/2026
Accepted 29/06/2026
Published 04/07/2026
Publication Time 27 Days
12

Login


My IP

PlumX Metrics